| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Indaptus Therapeutics, Inc.
13D/A
Amendment 3
INDP · 45339J105
|
27.3% |
10/22/2026
Event 10/16/2026
|
|||
|
Indaptus Therapeutics, Inc.
13D/A
Amendment 2
INDP · 45339J105
|
31.5% |
6/26/2026
Event 6/24/2026
|
|||
|
Indaptus Therapeutics, Inc.
13D/A
Amendment 1
INDP · 45339J105
|
37.1% |
4/29/2026
Event 4/28/2026
|
|||
| Yao Yun | 37.1% | ||||
| SINO LION VENTURES Ltd | 34.3% | ||||
| Xu Chenhao | 34.3% | ||||
| Dai Junyi | 9.9% | ||||
| Yang Ting | 9.9% | ||||
| Deng Lina | 4.9% | ||||
|
Indaptus Therapeutics, Inc.
13D
INDP · 45339J105
|
37.8% |
3/30/2026
Event 3/23/2026
|
|||
| Yao Yun | 37.8% | ||||
| SINO LION VENTURES Ltd | 35.0% | ||||
| Xu Chenhao | 35.0% | ||||
| Dai Junyi | 10.1% | ||||
| Yang Ting | 10.1% | ||||
| Deng Lina | 5.0% | ||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.